Low-dose add-back therapy during postoperative GnRH agonist treatment

Area of Science:

• Reproductive Endocrinology
• Pharmacology

Background:

• Gonadotropin-releasing hormone (GnRH) agonist treatment is used post-surgery for endometriosis.
• Add-back therapy is crucial to mitigate hypoestrogenic side effects.
• The optimal dosage of add-back therapy requires further investigation.

Purpose of the Study:

• To evaluate the efficacy of low-dose add-back therapy in managing hypoestrogenic side effects.
• To determine if low-dose add-back therapy maintains the therapeutic response of GnRH agonist treatment.
• To compare treatment dropout rates between low-dose and regular-dose add-back therapy groups.

Main Methods:

• A prospective cohort study involving 107 women undergoing postoperative GnRH agonist treatment.
• Patients received either once-daily (low-dose) or twice-daily (regular-dose) oral add-back therapy (estradiol valerate 1 mg and medroxyprogesterone acetate 2.5 mg) for 20 weeks.
• Assessment included recording of hypoestrogenic side effects, pelvic symptoms, pain, bone mineral density (L2-L4), and dropout rates.

Main Results:

• Incidence of hot flashes and insomnia was slightly lower in the low-dose group, though not statistically significant.
• Treatment dropout rates were lower in the low-dose group (9.6%) compared to the regular-dose group (14.5%).
• Both groups experienced significant loss of bone mineral density during therapy.

Conclusions:

• Low-dose add-back therapy effectively ameliorates hypoestrogenic side effects.
• It maintains the therapeutic response of GnRH agonist treatment.
• Low-dose add-back therapy presents a favorable treatment option due to reduced dropout rates.